Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
TRML is expected to report earnings to fall 45.95% to -20 cents per share on August 10
Q2'23
Est.
$-0.20
Q1'23
Beat
by $0.09
Q4'22
Missed
by $4.71
Q3'22
Missed
by $4.15
Q2'22
Missed
by $3.95
The last earnings report on May 11 showed earnings per share of -37 cents, beating the estimate of -45 cents. With 101.77K shares outstanding, the current market capitalization sits at 344.18M.